A study published in the New England Journal of Medicine shows there may be a combination of medicines that can cut the risk of recurring breast cancer by more than 40-percent.
More than 5,000 women with early stages of breast cancer participated in a study that combines Tamoxifen, a commonly used drug to treat breast cancer and an estrogen suppressant called Letrozole.
Women taking part in the study had estrogen receptor positive tumors, meaning the hormone estrogen actually fuels their cancer. But Letrozole stops the production of estrogen, while Tamoxifen blocks tumors from being stimulated.
The drugs were so successful the study was stopped after 2.5 years to give the treatment to those who were only on placebos. Researchers still have questions regarding long term and side effects, but its clear the combination can stop the recurrence of breast cancer tumors.